Community based approaches to the control of multidrug resistant tuberculosis: introducing "DOTS-plus".
作者信息
Farmer P, Kim J Y
机构信息
Department of Social Medicine, Harvard Medical School, 641 Huntington House, Boston, MA 02115, USA.
出版信息
BMJ. 1998 Sep 5;317(7159):671-4. doi: 10.1136/bmj.317.7159.671.
Abstract
摘要
相似文献
1
Community based approaches to the control of multidrug resistant tuberculosis: introducing "DOTS-plus".基于社区的耐多药结核病控制方法：引入“强化直接观察治疗策略”。
BMJ. 1998 Sep 5;317(7159):671-4. doi: 10.1136/bmj.317.7159.671.
2
DOTS and DOTS-plus: not the only answer.直接观察短程治疗（DOTS）及其强化版：并非唯一答案。
Ann N Y Acad Sci. 2001 Dec;953:165-84. doi: 10.1111/j.1749-6632.2001.tb11375.x.
3
Is DOTS-plus a feasible and cost-effective strategy?强化直接观察治疗策略（DOTS-plus）是否是一种可行且具有成本效益的策略？
PLoS Med. 2006 Sep;3(9):e350. doi: 10.1371/journal.pmed.0030350.
4
Curing multidrug-resistant tuberculosis: not all about the money.治愈耐多药结核病：并非全关乎金钱。
Lancet Respir Med. 2016 Nov;4(11):870-871. doi: 10.1016/S2213-2600(16)30335-6.
5
Multidrug-resistant tuberculosis--can the tide be turned?耐多药结核病——局势能扭转吗？
Lancet Infect Dis. 2001 Oct;1(3):199-202. doi: 10.1016/s1473-3099(01)00096-2.
6
Impact of DOTS compared with DOTS-plus on multidrug resistant tuberculosis and tuberculosis deaths: decision analysis.直接观察治疗短程化疗（DOTS）与强化版直接观察治疗短程化疗（DOTS-plus）对耐多药结核病及结核病死亡的影响：决策分析
BMJ. 2003 Mar 15;326(7389):574. doi: 10.1136/bmj.326.7389.574.
7
[Tuberculosis in the 21st centruy].《21世纪的结核病》
Enferm Infecc Microbiol Clin. 2000 May;18(5):207-8.
8
Programmatic versus personalised approaches to managing the global epidemic of multidrug-resistant tuberculosis.应对耐多药结核病全球流行的规划性方法与个性化方法
Lancet Respir Med. 2020 Apr;8(4):334-335. doi: 10.1016/S2213-2600(20)30104-1. Epub 2020 Feb 27.
9
Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany.在德国，将新型或第5组干预措施添加到背景治疗方案中用于治疗耐多药结核病的成本效益。
BMC Health Serv Res. 2017 Mar 8;17(1):182. doi: 10.1186/s12913-017-2118-2.
10
Can DOTS control multidrug-resistant tuberculosis?直接观察治疗短程化疗能否控制耐多药结核病？
Lancet. 2005;365(9466):1206-9. doi: 10.1016/S0140-6736(05)74788-7.
引用本文的文献
1
Whole-genome sequencing of clinical isolates from tuberculosis patients in India: real-world data indicates a high proportion of pre-XDR cases.对印度结核患者临床分离株进行全基因组测序：真实世界数据显示存在较高比例的预广泛耐药病例。
Microbiol Spectr. 2024 May 2;12(5):e0277023. doi: 10.1128/spectrum.02770-23. Epub 2024 Apr 10.
2
Addressing patients' unmet needs related to multidrug-resistant tuberculosis (MDR-TB) care: A qualitative research study from Pune city, India.解决耐多药结核病（MDR-TB）治疗相关的未满足患者需求：来自印度浦那市的一项定性研究。
PLoS One. 2023 Dec 28;18(12):e0295508. doi: 10.1371/journal.pone.0295508. eCollection 2023.
3
An Epidemic of Drug Resistance: Tuberculosis in the Twenty-First Century.耐药性流行：21世纪的结核病
Pathogens. 2023 Apr 27;12(5):652. doi: 10.3390/pathogens12050652.
4
Community Health Worker Program Outcomes for Diabetes and Hypertension Control in West Bank Refugee Camps: A Retrospective Matched Cohort Study.社区卫生工作者计划对约旦河西岸难民营糖尿病和高血压控制的影响：一项回顾性匹配队列研究。
Glob Health Sci Pract. 2022 Oct 31;10(5). doi: 10.9745/GHSP-D-22-00168.
5
Synthesis and biological evaluation of orally active prodrugs and analogs of para-aminosalicylic acid (PAS).对具有口服活性的对氨基水杨酸（PAS）前药和类似物的合成及生物评价。
Eur J Med Chem. 2022 Mar 15;232:114201. doi: 10.1016/j.ejmech.2022.114201. Epub 2022 Feb 19.
6
Bridging the gap between policy and practice: a qualitative analysis of providers' field experiences tinkering with directly observed therapy in patients with drug-resistant tuberculosis in Addis Ababa, Ethiopia.弥合政策与实践之间的差距：对埃塞俄比亚亚的斯亚贝巴耐多药结核病患者直接观察治疗中提供者现场经验的定性分析。
BMJ Open. 2020 Jun 16;10(6):e035272. doi: 10.1136/bmjopen-2019-035272.
7
Spondylodiscitis: experience of surgical management of complicated cases after failed antibiotic treatment.脊椎椎间盘炎：抗生素治疗失败后复杂病例的外科治疗经验
SICOT J. 2020;6:5. doi: 10.1051/sicotj/2020002. Epub 2020 Feb 14.
8
Intermittent treatment interruption and its effect on multidrug resistant tuberculosis treatment outcome in Ethiopia.间歇性治疗中断及其对埃塞俄比亚耐多药结核病治疗结局的影响。
Sci Rep. 2019 Dec 27;9(1):20030. doi: 10.1038/s41598-019-56553-1.
9
From peer-based to peer-led: redefining the role of peers across the hepatitis C care pathway: HepCare Europe.从同伴支持到同伴主导：重新定义丙型肝炎护理途径中同伴的角色：HepCare Europe。
J Antimicrob Chemother. 2019 Nov 1;74(Suppl 5):v17-v23. doi: 10.1093/jac/dkz452.
10
Determinants of mortality among patients with drug-resistant tuberculosis in northern Nigeria.尼日利亚北部耐多药结核病患者死亡的决定因素。
PLoS One. 2019 Nov 19;14(11):e0225165. doi: 10.1371/journal.pone.0225165. eCollection 2019.
本文引用的文献
1
The dilemma of MDR-TB in the global era.全球时代耐多药结核病的困境。
Int J Tuberc Lung Dis. 1998 Nov;2(11):869-76.
2
Population-based survey for drug resistance of tuberculosis--Mexico, 1997.1997年墨西哥基于人群的结核病耐药性调查。
MMWR Morb Mortal Wkly Rep. 1998 May 15;47(18):371-5.
3
Drug-resistant tuberculosis in Korea, 1994.1994年韩国的耐药结核病
Int J Tuberc Lung Dis. 1997 Aug;1(4):302-8.
4
Nosocomial transmission of multidrug-resistant Mycobacterium tuberculosis in Spain.西班牙耐多药结核分枝杆菌的医院内传播
Emerg Infect Dis. 1996 Apr-Jun;2(2):125-9. doi: 10.3201/eid0202.960208.
5
Control strategies for tuberculosis epidemics: new models for old problems.结核病流行的控制策略：针对老问题的新模型
Science. 1996 Jul 26;273(5274):497-500. doi: 10.1126/science.273.5274.497.
6
7
Improved outcomes for patients with multidrug-resistant tuberculosis.耐多药结核病患者的治疗效果得到改善。
Clin Infect Dis. 1995 Nov;21(5):1238-44. doi: 10.1093/clinids/21.5.1238.
8
Transmission of tuberculosis among the urban homeless.城市无家可归者中的结核病传播。
JAMA. 1996;275(4):305-7.
9
Transmission of tuberculosis to close contacts of patients with multidrug-resistant tuberculosis.耐多药结核病患者的密切接触者中结核病的传播。
Am J Respir Crit Care Med. 1996 Jan;153(1):331-5. doi: 10.1164/ajrccm.153.1.8542139.
10
Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin.171例耐异烟肼和利福平肺结核患者的治疗
N Engl J Med. 1993 Feb 25;328(8):527-32. doi: 10.1056/NEJM199302253280802.
Zotero 插件